Two of the FDA’s most senior vaccine leaders are exiting from their positions, raising fresh questions about the Biden administration and the way that it’s sidelined the FDA.
Marion Gruber, director of the FDA’s Office of Vaccines Research & Review and 32-year veteran of the agency, will leave at the end of October, and OVRR deputy director Phil Krause, who’s been at FDA for more than a decade, will leave in November. The news, first reported by BioCentury, is a massive blow to confidence in the agency’s ability to regulate vaccines.
The bombshell announcement comes at a particularly crucial moment, as boosters and children’s shots are being weighed by the regulator. The departures also come as the administration has recently jumped ahead of the FDA’s reviews of booster shots, announcing that they might be available by the week of Sept. 20.
And it’s no surprise. Read what The Hill reported today in an article titled “Biden officials weighing shorter timeline for booster shots”
President Biden on Friday said that discussions are underway over whether COVID-19 booster shots should be administered five months after second vaccine doses, a shorter timeline than the eight months previously discussed by health officials.
If we put these things together, it seems the CDC and the bumbling Biden administration is “weighing” quite heavily on the FDA to speed up the boosters of an already dangerous injection.